These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22682947)

  • 41. Definition, size of the problem, screening and diagnostic criteria: who should be screened, cost-effectiveness, and feasibility of screening.
    Jovanovic L
    Int J Gynaecol Obstet; 2009 Mar; 104 Suppl 1():S17-9. PubMed ID: 19155000
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The obesity-driven rising costs of type 2 diabetes in Australia: projections from the Fremantle Diabetes Study.
    Davis WA; Knuiman MW; Hendrie D; Davis TM
    Intern Med J; 2006 Mar; 36(3):155-61. PubMed ID: 16503950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparison of cost per case detected of screening strategies for Type 2 diabetes and impaired glucose regulation: modelling study.
    Khunti K; Gillies CL; Taub NA; Mostafa SA; Hiles SL; Abrams KR; Davies MJ
    Diabetes Res Clin Pract; 2012 Sep; 97(3):505-13. PubMed ID: 22554999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The cost of diagnosing Type 2 diabetes mellitus by clinical opportunistic screening in general practice.
    Pereira Gray DJ; Evans PH; Wright C; Langley P
    Diabet Med; 2012 Jul; 29(7):863-8. PubMed ID: 22313143
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impaired glucose tolerance and unidentified diabetes.
    Heine RJ; Mooy JM
    Postgrad Med J; 1996 Feb; 72(844):67-71. PubMed ID: 8871454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The economics of diabetes prevention.
    Herman WH
    Med Clin North Am; 2011 Mar; 95(2):373-84, viii. PubMed ID: 21281839
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of varying the screening interval on false positives and duration of undiagnosed disease in a screening programme for type 2 diabetes.
    Park PJ; Griffin SJ; Duffy SW; Wareham NJ
    J Med Screen; 2000; 7(2):91-6. PubMed ID: 11002449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. International Diabetes Federation Position Statement on the 1-hour post-load plasma glucose for the diagnosis of intermediate hyperglycaemia and type 2 diabetes.
    Bergman M; Tuomilehto J
    Diabetes Res Clin Pract; 2024 Apr; 210():111636. PubMed ID: 38537890
    [No Abstract]   [Full Text] [Related]  

  • 49. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk.
    Eastman RC; Cowie CC; Harris MI
    Diabetes Care; 1997 Feb; 20(2):127-8. PubMed ID: 9118758
    [No Abstract]   [Full Text] [Related]  

  • 50. The efficacy and cost of alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45-74 years of age.
    Johnson SL; Tabaei BP; Herman WH
    Diabetes Care; 2005 Feb; 28(2):307-11. PubMed ID: 15677784
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The economics of screening and treatment in type 2 diabetes mellitus.
    Raikou M; McGuire A
    Pharmacoeconomics; 2003; 21(8):543-64. PubMed ID: 12751913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Screening for NIDDM. Opportunities for detection, treatment, and prevention.
    Knowler WC
    Diabetes Care; 1994 May; 17(5):445-50. PubMed ID: 8062614
    [No Abstract]   [Full Text] [Related]  

  • 53. Development of an assessment tool for screening children for glucose intolerance by oral glucose tolerance test.
    Ehtisham S; Shaw N; Kirk J; Barrett T
    Diabetes Care; 2004 Jan; 27(1):280-1. PubMed ID: 14694009
    [No Abstract]   [Full Text] [Related]  

  • 54. Diagnosing the undiagnosed with diabetes.
    Home PD
    BMJ; 1994 Mar; 308(6929):611-2. PubMed ID: 8148705
    [No Abstract]   [Full Text] [Related]  

  • 55. Diabetes screening strategy holds potential for early treatment, savings.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Feb; 13(3):9-10, 12. PubMed ID: 12428636
    [No Abstract]   [Full Text] [Related]  

  • 56. Cost and effectiveness of screening methods for abnormal fasting plasma glucose among Thai adults participating in the annual health check-up at King Chulalongkorn Memorial Hospital.
    Srichang N; Jiamjarasrangsi W; Aekplakorn W; Supakankunti S
    J Med Assoc Thai; 2011 Jul; 94(7):833-41. PubMed ID: 21774291
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Medicare utilization, screening, and costs among participants in the Southeastern Diabetes Initiative: A population-based evaluation.
    Van Houtven CH; Greiner MA; Heidenfelder B; Spratt SE; Granger BB; Dunham AA; Qualls LG; Curtis LH
    Prim Care Diabetes; 2018 Apr; 12(2):172-183. PubMed ID: 29102500
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Obesity and co-morbidities in type 2 diabetes: an opportunity to bend the Health Care Cost Curve.
    Kristensen T; Yderstræde K
    Rev Clin Esp (Barc); 2014 Apr; 214(3):140-2. PubMed ID: 24530020
    [No Abstract]   [Full Text] [Related]  

  • 59. Screening for type 2 diabetes: an update of the evidence.
    Simmons RK; Echouffo-Tcheugui JB; Griffin SJ
    Diabetes Obes Metab; 2010 Oct; 12(10):838-44. PubMed ID: 20920035
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Global Increase in the Prevalence of Diabetes with Special Reference to the Middle East and Asia.
    Viswanathan V; Sathyamurthy S
    Diabetes Technol Ther; 2015 Oct; 17(10):676-8. PubMed ID: 26168052
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.